

Provider Newsflash



A fax bulletin for the Molina Healthcare of Washington Provider Network

Drug Formulary Benefit changes (Medicaid)

Dear Provider,

Thank you for providing excellent care to Molina Healthcare Apple Health (Medicaid) members.

We want to inform you of an upcoming change to the Molina Preferred Drug List (PDL) that may affect some of your patients managing type 2 diabetes.

Effective April 26, 2025, Januvia (sitagliptin), Janumet XR (sitagliptin/metformin XR), and Janumet (sitagliptin/metformin) will no longer be a preferred product. Generic alternatives of Zituvio (sitagliptin) and Zituvimet (sitagliptin/metformin) will be the new preferred options.

We understand that changes in medication coverage can be challenging for both providers and patients. Our goal is to ensure a smooth transition while continuing to support optimal patient care.

What You Need to Know:

- A new prescription is required for patients to begin therapy with Zituvio or Zituvimet.
- Zituvio and Zituvimet are **FDA-approved** for treating Type 2 Diabetes similar to Januvia, Januvia XR, and Janumet.
- Other preferred DPP4 inhibitors include: Saxagliptin HCl, Saxagliptin-Metformin ER, Tradjenta, Jentadueto, Jentadueto XR, Sitagliptin, Sitagliptin-Metformin

To help your patients avoid any disruptions in therapy, a 1-month override will be added from 04/26/2025 through 06/15/2025 for members currently established on these medications.

What We're Asking:

To help your patients avoid any disruptions in therapy, please review your records and submit new prescriptions to the pharmacy for **generic Zituvio (Sitagliptin) or generic Zituvimet (Sitagliptin/Metformin)** for affected individuals before **June 15, 2025**.

We greatly appreciate your continued partnership in providing quality care. If you have questions or need support during this transition, please don't hesitate to reach out to our team at (855) 322-4082, Monday through Friday, 7:30 a.m. – 6:30 p.m.

MHW Part# 0060RX-2504 MHW-04/28/2025